Yongkang Zhang1, James H Flory2,3, Yuhua Bao2. 1. Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA. yoz2009@med.cornell.edu. 2. Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA. 3. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND: The association between nonadherence to chronic medications and potentially preventable healthcare utilization and spending is largely unknown. OBJECTIVES: To examine the associations of chronic medication nonadherence with potentially preventable utilization and spending among patients who were prescribed diabetic medications, renin-angiotensin system antagonists (RASA) for hypertension, or statins for high cholesterol, and compare the associations by patient race/ethnicity and socioeconomic status. DESIGN: Retrospective cohort study. Medicare fee-for-service claims data from 2013 to 2016 for 177,881 patients. MEASURES: Medication nonadherence was defined as having a below 80% proportion of days covered in each 6-month interval after the index prescription. Potentially preventable utilization was measured by preventable emergency department visits and preventable hospitalizations. Potentially preventable spending was calculated as the geographically adjusted spending associated with preventable encounters. RESULTS: After adjustment for other patient characteristics, medication nonadherence was associated with a 1.7-percentage-point increase (95% confidence interval [CI]: 1.4 to 2.0 percentage points, p < 0.001) in the probability of preventable utilization among the diabetic medication cohort, a 1.7-percentage-point increase (95% CI: 1.5 to 1.9 percentage points, p < 0.001) among the RASA cohort, and a 1.0-percentage-point increase (95% CI: 0.8 to 1.1 percentage points, p < 0.001) among the statin cohort. Among patients with at least one preventable encounter, medication nonadherence was associated with $679-$898 increased preventable spending. The incremental probability of preventable utilization and incremental spending associated with nonadherence were higher among racial/ethnic minority and low socioeconomic groups. CONCLUSIONS: Improving medication adherence is a potential avenue to reducing preventable utilization and spending. Interventions are needed to address racial/ethnic and socioeconomic disparities.
BACKGROUND: The association between nonadherence to chronic medications and potentially preventable healthcare utilization and spending is largely unknown. OBJECTIVES: To examine the associations of chronic medication nonadherence with potentially preventable utilization and spending among patients who were prescribed diabetic medications, renin-angiotensin system antagonists (RASA) for hypertension, or statins for high cholesterol, and compare the associations by patient race/ethnicity and socioeconomic status. DESIGN: Retrospective cohort study. Medicare fee-for-service claims data from 2013 to 2016 for 177,881 patients. MEASURES: Medication nonadherence was defined as having a below 80% proportion of days covered in each 6-month interval after the index prescription. Potentially preventable utilization was measured by preventable emergency department visits and preventable hospitalizations. Potentially preventable spending was calculated as the geographically adjusted spending associated with preventable encounters. RESULTS: After adjustment for other patient characteristics, medication nonadherence was associated with a 1.7-percentage-point increase (95% confidence interval [CI]: 1.4 to 2.0 percentage points, p < 0.001) in the probability of preventable utilization among the diabetic medication cohort, a 1.7-percentage-point increase (95% CI: 1.5 to 1.9 percentage points, p < 0.001) among the RASA cohort, and a 1.0-percentage-point increase (95% CI: 0.8 to 1.1 percentage points, p < 0.001) among the statin cohort. Among patients with at least one preventable encounter, medication nonadherence was associated with $679-$898 increased preventable spending. The incremental probability of preventable utilization and incremental spending associated with nonadherence were higher among racial/ethnic minority and low socioeconomic groups. CONCLUSIONS: Improving medication adherence is a potential avenue to reducing preventable utilization and spending. Interventions are needed to address racial/ethnic and socioeconomic disparities.
Authors: Reethi N Iyengar; Dhanur S Balagere; Rochelle R Henderson; Abbey L LeFrancois; Rebecca M Rabbitt; Sharon Glave Frazee Journal: J Manag Care Spec Pharm Date: 2014-08
Authors: Michael F Pesko; Andrew M Ryan; Stephen M Shortell; Kennon R Copeland; Patricia P Ramsay; Xuming Sun; Jayme L Mendelsohn; Diane R Rittenhouse; Lawrence P Casalino Journal: Health Serv Res Date: 2017-09-21 Impact factor: 3.402
Authors: Shreya Kangovi; Frances K Barg; Tamala Carter; Judith A Long; Richard Shannon; David Grande Journal: Health Aff (Millwood) Date: 2013-07 Impact factor: 6.301
Authors: Dina Hafez; Laurence F McMahon; Linda Balogh; Floyd John Brinley; John Crump; Mark Ealovega; Audrey Fan; Yeong Kwok; Kristen Krieger; Thomas O'Connor; Elisa Ostafin; Heidi Reichert; Jennifer Meddings Journal: Am J Manag Care Date: 2018-03-01 Impact factor: 2.229
Authors: Rainu Kaushal; George Hripcsak; Deborah D Ascheim; Toby Bloom; Thomas R Campion; Arthur L Caplan; Brian P Currie; Thomas Check; Emme Levin Deland; Marc N Gourevitch; Raffaella Hart; Carol R Horowitz; Isaac Kastenbaum; Arthur Aaron Levin; Alexander F H Low; Paul Meissner; Parsa Mirhaji; Harold A Pincus; Charles Scaglione; Donna Shelley; Jonathan N Tobin Journal: J Am Med Inform Assoc Date: 2014-05-12 Impact factor: 4.497